ClinicalTrials.gg
CompletedNCT00372424Updated Dec 28, 2012Results posted

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

A Phase 1 interventional study of Herceptin and Sunitinib in Breast Cancer, sponsored by Pfizer. Completed at 7 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-28.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
299th of 366
26 · median 61
Started
2006
with 17 others
Phase 1
21 of 374
3 open now
Registered
72nd of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 299th largest by enrollment of the 366 interventional ones that give a count, is one of 18 that started in 2006, is one of 21 in phase 1, and was the 72nd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing Her-2, who have not received chemotherapy treatment in the advanced disease setting.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer over-expressing HER2. First-line treatment with sunitinib/docetaxel/trastuzumab.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breast cancer with evidence of unresectable, locally recurrent, or disease.
  • Tumors over-expressing Her-2
  • Candidate for treatment with docetaxel/trastuzumab

Exclusion criteria

Exclusion Criteria:

  • Histology of inflammatory carcinoma
  • and/or ALT >1.5 x concomitant with ALP >2.5 x ULN
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    Combination of SU011248 (37.5 mg once daily \[Schedule 2/1\]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)

    Drug: Herceptin · Drug: Sunitinib · Drug: Taxotere

Interventions

  • Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.

    Also known as: trastuzumab

  • SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.

    Also known as: Sutent

  • The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.

    Also known as: docetaxel

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From screening until 28 days post last dose of study drug

Secondary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all target lesions. PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)

  2. Progression-free Survival (PFS)

    Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)

  3. Duration of Response (DR)

    Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)

  4. Plasma Trough Concentrations (Ctrough) of SU011248 (Sunitinib), SU012662 (Sunitinib Metabolite) and Total Drug (SU011248+SU012662)

    Ctrough = the concentration prior to study medication administration. Ctrough was calculated for SU011248 (Sunitinib), SU012662 (Sunitinib metabolite) and total drug (SU011248+SU012662). Concentration values below the lower limit of quantification were taken as zero.

    Time frame: Pre-dose (0 hours [H]) on Day 1 and Day 15 of Cycle 2, 4, 6 and additionally Day 15 of Cycle 1

  5. Maximum Observed Plasma Concentration (Cmax) of Docetaxel

    Concentration values below the lower limit of quantification were taken as zero.

    Time frame: End of infusion (1 H) on Day 1 of Cycle 1, 2, 4 and 6

  6. Plasma Trough Concentrations (Ctrough) of Trastuzumab

    Ctrough = the concentration prior to study medication administration.

    Time frame: Weekly trastuzumab: Pre-dose (0 H) on Day 1 and 15 of Cycle 1, 2, 4 and 6; 3-weekly trastuzumab: Pre-dose (0 H) on Day 1 of Cycle 1, 2, 4 and 6

Other outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Paclitaxel

    Time frame: End of infusion (1 H) on Day 1 of Cycle 1, 2, 4 and 6

07

Results

Posted Oct 30, 2012

Participant flow

Participant flow — Overall Study
MilestoneSunitinib + Docetaxel + Trastuzumab
Started26
Treated25
Completed0
Not completed26
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Withdrew: Death1
Withdrew: Objective progression or relapse14
Withdrew: Other7
Withdrew: Enrolled, not treated1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From screening until 28 days post last dose of study drug
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
participantsSunitinib + Docetaxel + Trastuzumab
AEs24
SAEs11
SecondaryPercentage of Participants With Objective Response (OR)

Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all target lesions. PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsSunitinib + Docetaxel + Trastuzumab
Percentage of Participants With Objective Response (OR)72.7 (49.8 to 89.3)
SecondaryProgression-free Survival (PFS)

Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)
Reported as:
Median · weeks
Progression-free Survival (PFS)
weeksSunitinib + Docetaxel + Trastuzumab
Progression-free Survival (PFS)58.4 (37.0 to 66.1)
SecondaryDuration of Response (DR)

Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)
Reported as:
Median · weeks
Duration of Response (DR)
weeksSunitinib + Docetaxel + Trastuzumab
Duration of Response (DR)51.3 (32.0 to 60.1)
SecondaryPlasma Trough Concentrations (Ctrough) of SU011248 (Sunitinib), SU012662 (Sunitinib Metabolite) and Total Drug (SU011248+SU012662)

Ctrough = the concentration prior to study medication administration. Ctrough was calculated for SU011248 (Sunitinib), SU012662 (Sunitinib metabolite) and total drug (SU011248+SU012662). Concentration values below the lower limit of quantification were taken as zero.

Time frame:
Pre-dose (0 hours [H]) on Day 1 and Day 15 of Cycle 2, 4, 6 and additionally Day 15 of Cycle 1
Reported as:
Mean · nanogram/milliliter (ng/mL)
Plasma Trough Concentrations (Ctrough) of SU011248 (Sunitinib), SU012662 (Sunitinib Metabolite) and Total Drug (SU011248+SU012662)
nanogram/milliliter (ng/mL)Sunitinib + Docetaxel + Trastuzumab
Sunitinib: Cycle1/Day15 (n= 19)40.17 ± 32.17
Sunitinib: Cycle2/Day1 (n= 17)5.96 ± 6.17
Sunitinib: Cycle2/Day15 (n= 16)37.29 ± 31.07
Sunitinib: Cycle4/Day1 (n= 17)5.26 ± 5.71
Sunitinib: Cycle4/Day15 (n= 16)43.21 ± 27.31
Sunitinib: Cycle6/Day1 (n= 16)3.36 ± 4.34
Sunitinib: Cycle6/Day15 (n= 13)28.46 ± 21.19
Sunitinib Metabolite: Cycle1/Day15 (n= 19)16.15 ± 12.09
Sunitinib Metabolite: Cycle2/Day1 (n= 17)4.76 ± 3.92
Sunitinib Metabolite: Cycle2/Day15 (n= 16)14.43 ± 11.34
Sunitinib Metabolite: Cycle4/Day1 (n= 17)3.95 ± 2.57
Sunitinib Metabolite: Cycle4/Day15 (n= 16)17.62 ± 11.17
Sunitinib Metabolite: Cycle6/Day1 (n= 16)2.96 ± 2.89
Sunitinib Metabolite: Cycle6/Day15 (n= 13)11.54 ± 9.66
Total Drug: Cycle1/Day15 (n= 19)56.31 ± 42.70
Total Drug: Cycle2/Day1 (n= 17)10.72 ± 9.80
Total Drug: Cycle2/Day15 (n= 16)51.72 ± 41.45
Total Drug: Cycle4/Day1 (n= 17)9.21 ± 7.97
Total Drug: Cycle4/Day15 (n= 16)60.83 ± 37.43
Total Drug: Cycle6/Day1 (n= 16)6.32 ± 7.02
Total Drug: Cycle6/Day15 (n= 13)40.00 ± 30.04
SecondaryMaximum Observed Plasma Concentration (Cmax) of Docetaxel

Concentration values below the lower limit of quantification were taken as zero.

Time frame:
End of infusion (1 H) on Day 1 of Cycle 1, 2, 4 and 6
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Docetaxel
ng/mLSunitinib + Docetaxel + Trastuzumab
Cycle1/Day1 (n= 23)1117.05 ± 1159.53
Cycle2/Day1 (n= 19)1388.63 ± 1260.94
Cycle4/Day1 (n= 16)1316.88 ± 1096.97
Cycle6/Day1 (n= 15)1670.40 ± 1614.07
SecondaryPlasma Trough Concentrations (Ctrough) of Trastuzumab

Ctrough = the concentration prior to study medication administration.

Time frame:
Weekly trastuzumab: Pre-dose (0 H) on Day 1 and 15 of Cycle 1, 2, 4 and 6; 3-weekly trastuzumab: Pre-dose (0 H) on Day 1 of Cycle 1, 2, 4 and 6

No measurements were reported for this outcome.

Other pre-specifiedMaximum Observed Plasma Concentration (Cmax) of Paclitaxel
Time frame:
End of infusion (1 H) on Day 1 of Cycle 1, 2, 4 and 6

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sunitinib + Docetaxel + Trastuzumab—11/25 (44%)23/25 (92%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSunitinib + Docetaxel + Trastuzumab
Febrile neutropeniaBlood and lymphatic system disorders4/25
NeutropeniaBlood and lymphatic system disorders3/25
DiarrhoeaGastrointestinal disorders1/25
Intestinal perforationGastrointestinal disorders1/25
Rectal haemorrhageGastrointestinal disorders1/25
StomatitisGastrointestinal disorders1/25
VomitingGastrointestinal disorders1/25
FatigueGeneral disorders1/25
Multi-organ failureGeneral disorders1/25
ErysipelasInfections and infestations1/25
Most frequent other events
Showing 10 of 53
Most frequent other events
EventSunitinib + Docetaxel + Trastuzumab
DiarrhoeaGastrointestinal disorders15/25
FatigueGeneral disorders15/25
NeutropeniaBlood and lymphatic system disorders14/25
PyrexiaGeneral disorders13/25
NauseaGastrointestinal disorders11/25
EpistaxisRespiratory, thoracic and mediastinal disorders9/25
MyalgiaMusculoskeletal and connective tissue disorders8/25
Abdominal pain upperGastrointestinal disorders7/25
StomatitisGastrointestinal disorders7/25
VomitingGastrointestinal disorders7/25

Baseline characteristics

Age Continuous
Age Continuous(years)Sunitinib + Docetaxel + Trastuzumab
Mean57.0 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Sunitinib + Docetaxel + Trastuzumab
Female25
Male0
08

Study locations

7 sites
  • Pfizer Investigational Site
    Bruxelles, 1000, Belgium
  • Pfizer Investigational Site
    Bruxelles, 1200, Belgium
  • Pfizer Investigational Site
    Charleroi, 6000, Belgium
  • Pfizer Investigational Site
    Sint-Niklaas, 9100, Belgium
  • Pfizer Investigational Site
    Wilrijk, 2610, Belgium
  • Pfizer Investigational Site
    Meldola, FC 47014, Italy
  • Pfizer Investigational Site
    Milano, 20132, Italy
09

References and documents

Publications

  • Cardoso F, Canon JL, Amadori D, Aldrighetti D, Machiels JP, Bouko Y, Verkh L, Usari T, Kern KA, Giorgetti C, Dirix L. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Breast. 2012 Dec;21(6):716-23. doi: 10.1016/j.breast.2012.09.002. Epub 2012 Sep 27. PubMed 23022045 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2006
First posted
Sep 7, 2006
Start
Dec 2006
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Oct 30, 2012
Last update
Dec 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00372424
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 7, 2006
Start date
Dec 2006
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Oct 30, 2012
Last update
Dec 28, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Docetaxel

Start the discussion